Class III — Low Risk Severity Status: Ongoing Authority: FDA

LEVOTHYROXINE SODIUM

Recalling Firm / Manufacturer: Macleods Pharmaceuticals Ltd (Mumbai, India)
FDA Recall Number: D-0470-2025
View FDA Source
Source Authority Disclaimer: This drug recall notice is published by Questo using official enforcement reports issued by the U.S. Food & Drug Administration (FDA). It is provided for informational, academic, and clinical research purposes only. Patients should not discontinue prescribed treatments without consulting their physician or pharmacist.
Product & Identification Information
Brand, active ingredients, NDC codes, and manufacturer details
Brand / Trade Name
LEVOTHYROXINE SODIUM
Generic Name
LEVOTHYROXINE SODIUM
Active Substance(s)
Levothyroxine Sodium
Administration Route
Oral
National Drug Code (NDC)
33342-393
Total Quantity Recalled
1,344- 1000 count bottles
Official Reason for Recall
Specific hazard or quality defect cited by the FDA

According to the official FDA enforcement report:

Presence of a foreign substance: black hair found embedded in tablet.

Full Product Description
Packaging specifications and labeling details

Levothyroxine Sodium Tablets, USP 112 mcg (0.112mg), 1000 tablets, Rx Only, Manufactured for: Macleods Pharma USA, Inc. Princeton, NJ 08540. Manufactured by: Macleods Pharmaceuticals Ltd. Sarigam, Valsad, Gujarat, India, NDC 33342-398-44.

Enforcement & Regulatory Details
FDA classification, report dates, and initiation authority
Health Hazard Classification
Class III
Current Action Status
Ongoing
FDA Enforcement Report Date
June 18, 2025
Firm Initiation Date
May 29, 2025
FDA Classification Date
Jun 12, 2025
Initiation Type
Voluntary: Firm initiated
Affected Lots & Batch Numbers
Product codes, lot numbers, and expiration dates
Lot #: MLF2401A, Exp 01/31/2026
Distribution Information
Geographic scope of affected shipments

Nationwide in the USA

Safety Guidance & Actions
Standard FDA protocol for patients and healthcare providers
Advisory Notice
This Class III recall involves technical or packaging non-conformities that are not expected to cause adverse health consequences. Consult your pharmacist if you have questions.

Official Source Provenance

Verified regulatory citation from U.S. FDA OpenFDA

Primary Data Source: U.S. Food & Drug Administration (FDA) OpenFDA API
Recall Number: D-0470-2025
Questo Retrieval Date: July 31, 2026 14:36 1785508616UTCC
View Official FDA Source

System Notice

Confirm Action